首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   7741篇
  免费   880篇
  国内免费   99篇
耳鼻咽喉   36篇
儿科学   1002篇
妇产科学   56篇
基础医学   573篇
口腔科学   85篇
临床医学   542篇
内科学   1968篇
皮肤病学   182篇
神经病学   151篇
特种医学   132篇
外科学   2864篇
综合类   250篇
预防医学   176篇
眼科学   86篇
药学   250篇
中国医学   33篇
肿瘤学   334篇
  2023年   248篇
  2022年   160篇
  2021年   292篇
  2020年   494篇
  2019年   555篇
  2018年   502篇
  2017年   458篇
  2016年   373篇
  2015年   326篇
  2014年   501篇
  2013年   589篇
  2012年   398篇
  2011年   426篇
  2010年   364篇
  2009年   330篇
  2008年   331篇
  2007年   310篇
  2006年   323篇
  2005年   290篇
  2004年   228篇
  2003年   182篇
  2002年   165篇
  2001年   131篇
  2000年   96篇
  1999年   85篇
  1998年   48篇
  1997年   47篇
  1996年   37篇
  1995年   53篇
  1994年   56篇
  1993年   43篇
  1992年   54篇
  1991年   31篇
  1990年   24篇
  1989年   16篇
  1988年   23篇
  1987年   21篇
  1986年   25篇
  1985年   23篇
  1984年   11篇
  1983年   8篇
  1982年   15篇
  1981年   8篇
  1980年   4篇
  1979年   5篇
  1978年   2篇
  1977年   3篇
  1976年   3篇
  1975年   1篇
  1974年   2篇
排序方式: 共有8720条查询结果,搜索用时 15 毫秒
1.
2.
BackgroundPrevious studies have demonstrated that solid organ transplant (SOT) patients undergoing primary total knee arthroplasty (TKA) are at an increased risk of postoperative complications. The purpose of this study is to utilize a large, national database to investigate revision TKA (rTKA) outcomes in SOT patients.MethodsThis was a retrospective review utilizing the Nationwide Readmissions Database (NRD) and ICD-9 codes to identify patients who underwent rTKA from 2010-2014 with a history of at least one SOT. Propensity-score-matching (PSM) was used to compare rTKA outcomes in SOT patients compared to matched patients without SOT.ResultsA total of 303,867 rTKAs, with 464 of those being performed in SOT patients, were included in the study. Of these, 71,903 and 182 were performed for PJI in non-SOT and SOT patients, respectively. rTKA was performed most frequently in kidney transplant patients (53.0%) followed by liver transplant patients (34.3%). For non-PJI patients, SOT patients had a higher 90-day readmission rate than matched non-SOT rTKA patients (23.2% vs 12.6%, p = 0.006). However, there were no differences in 90-day readmission rates for specific rTKA complications, subsequent revision rTKA, or mortality. Among patients undergoing rTKA for PJI, there was no difference in overall 90-day readmission rate, readmission for specific rTKA complications, subsequent revision rTKA, or mortality.ConclusionsWhile the increased medical comorbidities associated with SOT place patients at increased risk for complications following rTKA, it appears that SOT alone does not do so when patients are matched based on overall medical comorbidity.  相似文献   
3.
胰腺移植和胰肾联合移植是治疗1型糖尿病和部分2型糖尿病及其并发症导致的肾衰竭的最佳治疗方法。胰腺移植的类型主要包括同期胰肾联合移植(SPK)、肾移植后胰腺移植(PAK)和单纯胰腺移植(PTA)。在所有的胰腺移植类型中,对移植胰腺的活组织检查(活检)仍然是明确诊断其排斥反应并与其他并发症进行鉴别的最佳方法。本文对移植胰腺活检的方法及其相关的研究进展、移植胰腺活检排斥反应诊断标准及其进展、移植胰腺主要的并发症及其病理学表现进行阐述,旨在为指导临床对上述并发症予以准确诊断,良好地保障移植胰腺和受者的长期存活提供参考。  相似文献   
4.
Over the last 40 years, the incidence and prevalence of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) have continued to increase. Compared to other epithelial neoplasms in the same organ, GEP-NENs exhibit indolent biological behavior, resulting in more chances to undergo surgery. However, the role of surgery in high-grade or advanced GEP-NENs is still controversial. Surgery is associated with survival improvement of well-differentiated high-grade GEP-NENs, whereas poorly differentiated GEP-NENs that may benefit from resection require careful selection based on Ki67 and other tissue biomarkers. Additionally, surgery also plays an important role in locally advanced and metastatic disease. For locally advanced GEP-NENs, isolated major vascular involvement is no longer an absolute contraindication. In the setting of metastatic GEP-NENs, radical intended surgery is recommended for patients with low-grade and resectable metastases. For unresectable metastatic disease, a variety of surgical approaches, including cytoreduction of liver metastasis, liver transplantation, and surgery after neoadjuvant treatment, show survival benefits. Primary tumor resection in GEP-NENs with unresectable metastatic disease is associated with symptom control, prolonged survival, and improved sensitivity toward systemic therapies. Although there is no established neoadjuvant or adjuvant strategy, increasing attention has been given to this emerging research area. Some studies have reported that neoadjuvant therapy effectively reduces tumor burden, improves the effectiveness of subsequent surgery, and decreases surgical complications.  相似文献   
5.
目的:研究纤维蛋白粘合剂(FS)粘贴的双层角膜基质透镜体内生物相容性,探讨使用该种材料行角膜移植的可行性。

方法:选取健康清洁级新西兰白兔15只,采用自身对照,以兔右眼为实验眼,左眼为对照眼。实验眼使用FS粘贴的双层角膜基质透镜作为移植材料行板层角膜移植手术,对照眼不进行人工干预。分别于术后7、14、28d使用手持裂隙灯观察双眼角膜情况,并进行生物相容性评分,同时取双眼角膜行HE染色进行组织病理学检测,观察角膜恢复情况。

结果:裂隙灯观察结果显示,至角膜移植术后28d,实验眼角膜上皮生长情况良好,角膜透明度基本恢复,水肿程度减轻,新生血管生长至角膜缘后未加重,未见上皮、内皮排斥线等排斥反应; 对照眼角膜透明,角膜上皮光滑。生物相容性评分结果显示,角膜移植术后实验眼角膜植片水肿程度逐渐减轻,透明度逐渐恢复,排斥反应较小,角膜植片的生物相容性较好; 至术后28d,实验眼和对照眼角膜透明度、水肿程度及新生血管生长程度均无差异(P>0.01)。组织病理学检测结果显示,至角膜移植术后28d,实验眼植片表面有4~5层角膜上皮细胞覆盖,角膜胶原排列整齐、规则,植片内未见明显炎性细胞浸润,双片透镜间分界消失,层间FS被机体完全吸收,植片与植床融合,未见明显分界。

结论:使用FS粘贴的双层角膜基质透镜作为植片行板层角膜移植术后恢复较好,排斥反应较小,生物相容性较好,可用于板层角膜移植。  相似文献   

6.
7.
8.
9.
BackgroundConsiderable progress has been made in therapeutic options for multiple myeloma (MM). Understanding the current landscape of MM treatment options and associated outcomes in the real world is important in providing key insights into clinical and knowledge gaps which could be targeted for further optimization.MethodsThe Canadian Myeloma Research Group Database (CMRG-DB) is a prospectively maintained disease-specific database with >7000 patients. The objective of this study was to describe the trends in the treatment landscape and outcomes including early mortality, time to next treatment, and overall survival (OS) in each line of treatment stratified by autologous stem cell transplant (ASCT) receipt among newly-diagnosed MM patients in Canada between 2007 and 2018.ResultsA total of 5154 patients were identified among which 3030 patients (58.8%) received an upfront ASCT and 2124 (41.2%) did not. At diagnosis, the median age was 64 years and 58.6% were males. Bortezomib and lenalidomide were most frequently used (>50%) in first and second-line treatment respectively among both the ASCT and non-ASCT cohort. The median OS was 122.0 months (95% Cl 115.0-135.0 months) and 54.3 months (95% CI 50.8-58.8 months) for the ASCT and non-ASCT cohort respectively with an incremental decrease in OS in each subsequent line of treatment.ConclusionWe present the largest study to date in the Canadian landscape showing the characteristics, therapy usage, and outcomes among MM patients. This information will be critical in benchmarking current outcomes and provide key insight into areas of unmet needs and gaps for improvement of MM patients nationally.  相似文献   
10.
ObjectiveThis study sought to evaluate the effectiveness of diltiazem at achieving a targeted heart rate (HR) of ≤75 bpm in orthotopic heart transplant patients during coronary computed tomography (CT) angiography.MethodsBaseline heart rates were compared to heart rates after diltiazem administration in 25 adult orthotopic heart transplant subjects being monitored by electrocardiogram (ECG) gaiting on a multidetector CT scanner.ResultsThe mean baseline HR of the group was 84.28 ± 11.305 bpm. After diltiazem administration, the mean heart rate of the group at the time of the coronary CT angiography study was 75.32 ± 9.49 bpm. Heart rates decreased in 23 subjects (92%) and the targeted heart rate of ≤75 bpm was observed in 13 subjects (52%).ConclusionDiltiazem administration was associated with a decrease in heart rate, yet reaching the targeted heart rate was limited. Further study regarding diltiazem dosing and its impact is warranted.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号